Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR mutation
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
EGFR exon 19 deletion + EGFR T790M (10)
EGFR mutation + PD-L1 overexpression (8)
MET amplification + EGFR mutation (8)
EGFR exon 19 deletion + PD-L1 overexpression (5)
EGFR mutation + MET amplification (5)
EGFR mutation + PD-L1 expression (5)
EGFR exon 19 deletion + EGFR L643V (4)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation (4)
PD-L1 expression + EGFR mutation (4)
TA-MUC1 elevation + EGFR expression (4)
TNFRSF10A overexpression + EGFR mutation (4)
EGFR exon 19 deletion + EGFR G724S (3)
EGFR exon 19 deletion + NRAS Q61K (3)
EGFR exon 19 deletion + PTEN K237Cfs*17 (3)
EGFR mutation + ANKRD1 overexpression (3)
EGFR mutation + EGFR amplification (3)
EGFR mutation + MET overexpression (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
MET overexpression + EGFR mutation (3)
AXL expression + EGFR mutation (2)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion + TMB-L (2)
EGFR L858R + EGFR exon 19 deletion (2)
EGFR L858R + PD-L1 overexpression (2)
EGFR L858R + VOPP1-EGFR fusion + EGFR T790M (2)
EGFR exon 19 deletion + MET amplification (2)
EGFR exon 19 deletion + EGFR K754E (2)
EGFR exon 19 deletion + EGFR L861Q + EGFR G873E (2)
EGFR exon 19 deletion + KRAS mutation (2)
EGFR exon 19 deletion + PD-L1 expression (2)
EGFR exon 19 deletion + TP53 mutation + RB1 mutation (2)
EGFR exon 20 insertion + EGFR amplification (2)
EGFR mutation + BCL2L11 deletion (2)
EGFR mutation + CDCA3 underexpression (2)
EGFR mutation + PTEN deletion (2)
EGFR mutation + RET fusion (2)
EGFR mutation + YAP1 overexpression (2)
EGFR mutation + YES1 overexpression (2)
EGFR-SEPTIN14 fusion + EGFR amplification (2)
EGFR exon 19 deletion + MET Amplification + MET D1228V (2)
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)
ERBB3 mutation + TMB-H (2)
HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)
PD-L1 overexpression + EGFR mutation (2)
TMB-H + EGFR exon 19 deletion (2)
TMB-H + EGFR mutation (2)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
APC V2194fs + EGFR amplification + EGFR-SEPTIN14 fusion (1)
APOA1 elevation + EGFR T790M (1)
ARID1A underexpression + EGFR mutation (1)
ATM expression + ATM T2333fs* + EGFR negative (1)
AXL overexpression + EGFR mutation (1)
AXL underexpression + EGFR mutation (1)
BCL2L11 deletion + EGFR T790M (1)
BRAF V600E + EGFR expression (1)
CCDC6-RET fusion + EGFR mutation (1)
CD276 underexpression + EGFR mutation (1)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)
CRKL overexpression + EGFR mutation (1)
EGFR C797S + KRAS amplification + RB1 deletion (1)
EGFR C797S + MET amplification (1)
EGFR E746_A750del + KRAS amplification (1)
EGFR G719A + EGFR S768I + PD-L1 overexpression (1)
EGFR G719A + PD-L1 overexpression (1)
EGFR G719D + EGFR L861Q + CUX1-MET fusion (1)
EGFR L747P + PD-L1 overexpression (1)
EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification (1)
EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)
EGFR L858R + KDR overexpression + VEGFC overexpression (1)
EGFR L858R + KRAS amplification + RB1 deletion (1)
EGFR L858R + MET amplification (1)
EGFR L858R + MET overexpression (1)
EGFR L858R + MET positive (1)
EGFR L858R + PD-L1 expression (1)
EGFR L858R + PD-L1 underexpression (1)
EGFR L858R + ROS1 fusion (1)
EGFR L858R + ROS1-ADGRG6 fusion (1)
EGFR L858R + TMB-H (1)
EGFR L858R + VEGFA-L (1)
EGFR P719A + PD-L1 overexpression (1)
EGFR T263P + EGFR L858R + MET amplification (1)
EGFR T790M + HER-2 amplification (1)
EGFR T790M + KRAS amplification + RB1 deletion (1)
EGFR T790M + MET amplification (1)
EGFR T790M + MET positive (1)
EGFR T790M + MYC amplification (1)
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)
EGFR T790M + TMB-H (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + ALK amplification (1)
EGFR exon 19 deletion + BRAF G464A (1)
EGFR exon 19 deletion + CCND1 overexpression (1)
EGFR exon 19 deletion + EGFR L747S (1)
EGFR exon 19 deletion + EGFR S768I (1)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)
EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)
EGFR exon 19 deletion + EGFR exon 21 mutation + TP53 mutation (1)
EGFR exon 19 deletion + LMNA-NTRK1 fusion + EGFR T790M (1)
EGFR exon 19 deletion + MET positive (1)
EGFR exon 19 deletion + MET amplification (1)
EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y (1)
EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C (1)
EGFR exon 19 deletion + PD-L1 underexpression (1)
EGFR exon 19 deletion + PTEN deletion + PIK3CA overexpression (1)
EGFR exon 19 deletion + RBM10 S167* (1)
EGFR exon 19 deletion + STRN-ALK fusion (1)
EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)
EGFR exon 19 deletion + TP53 mutation + MET amplification (1)
EGFR exon 19 deletion + VEGFA-L (1)
EGFR exon 20 insertion + PD-L1 overexpression (1)
EGFR exon 20 insertion + TP53 mutation (1)
EGFR expression + KRAS G12C (1)
EGFR expression + TP53 mutation (1)
EGFR fusion + PD-L1 overexpression (1)
EGFR mutation + ALK negative + TMB-H (1)
EGFR mutation + BCL2L11 overexpression (1)
EGFR mutation + BRCA1 overexpression (1)
EGFR mutation + BRCA1 underexpression (1)
EGFR mutation + CCND1 expression + CDKN2A deletion (1)
EGFR mutation + CD73 overexpression (1)
EGFR mutation + Chr 14q31.1-q31.3 (1)
EGFR mutation + Chr 1p13.3-p13.1 (1)
EGFR mutation + EGFR amplification + MET amplification + MTAP deletion (1)
EGFR mutation + ER positive (1)
EGFR mutation + LANCL2 overexpression (1)
EGFR mutation + LINC00460 overexpression (1)
EGFR mutation + MET amplification + EGFR amplification (1)
EGFR mutation + MET amplification + TP53 mutation (1)
EGFR mutation + MET overexpression + MET amplification (1)
EGFR mutation + MET-CEP7 fusion (1)
EGFR mutation + PD-L1 elevation (1)
EGFR mutation + PD-L1 expression + TP53 mutation (1)
EGFR mutation + PD-L1 negative (1)
EGFR mutation + RBBP8 underexpression (1)
EGFR mutation + ROMO1 overexpression (1)
EGFR mutation + RPS6KB1 amplification (1)
EGFR mutation + S100A9 overexpression (1)
EGFR mutation + SYK overexpression (1)
EGFR mutation + TP53 expression (1)
EGFR mutation + TSLP underexpression (1)
EGFR mutation + TTF1 negative (1)
EGFR mutation + WNT5A expression (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR negative + S100A8 elevation (1)
EGFR negative + S100A9 elevation (1)
EGFR negative + SAA1 elevation (1)
EGFR negative + SAA2 elevation (1)
EGFR overexpression + BRAF V600E (1)
EGFR overexpression + BRAF mutation (1)
EGFR overexpression + KRAS 13D (1)
EGFR overexpression + KRAS mutation (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
EGFR wild-type + Chr 11p11.11-q12.1 (1)
EGFR wild-type + Chr 7q31.1-q31.31 (1)
EGFR wild-type + Chr 9q21.31-q22.2 (1)
EGFR wild-type + MET amplification (1)
EGFR wild-type + MET overexpression (1)
EGFR-SEC61G fusion + EGFR amplification (1)
EGFRvIII mutation + EGFR-SEPTIN14 fusion + EGFR amplification (1)
EPHA2 expression + EGFR mutation (1)
ERCC2 positive + SYP negative + EGFR exon 21 mutation (1)
GPRC6A-RET fusion + EGFR mutation (1)
HER-2 amplification + EGFR mutation (1)
HR negative + EGFR amplification (1)
KIF5B-RET fusion + EGFR exon 19 deletion (1)
KRAS mutation + EGFR amplification (1)
MET exon 14 mutation + EGFR wild-type (1)
MET negative + EGFR mutation (1)
MET overexpression + EGFR wild-type (1)
MET positive + EGFR mutation (1)
NOTCH2-NTRK1 fusion + EGFR L858R (1)
PD-L1 underexpression + EGFR mutation (1)
PTGS2 positive + MET positive + PBK positive + EGFR mutation (1)
RBM10 deletion + EGFR mutation (1)
RBM10 underexpression + EGFR mutation (1)
ROS1 translocation + EGFR wild-type (1)
SHTN1-RET fusion + EGFR mutation (1)
SPECC1-RET fusion + EGFR mutation (1)
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)
TERT mutation + EGFR T790M + EGFR exon 20 insertion (1)
TLN1-RET fusion + EGFR mutation (1)
TRIM24-RET fusion + EGFR mutation (1)
TRIM33-RET fusion + EGFR mutation (1)
CALR elevation + EGFR mutation (0)
HER-2 positive + FGFR1 amplification (0)
PD-L1 underexpression + EGFR wild-type (0)
EGFR exon 19 deletion + EGFR T790M (10)
EGFR mutation + PD-L1 overexpression (8)
MET amplification + EGFR mutation (8)
EGFR exon 19 deletion + PD-L1 overexpression (5)
EGFR mutation + MET amplification (5)
EGFR mutation + PD-L1 expression (5)
EGFR exon 19 deletion + EGFR L643V (4)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation (4)
PD-L1 expression + EGFR mutation (4)
TA-MUC1 elevation + EGFR expression (4)
TNFRSF10A overexpression + EGFR mutation (4)
EGFR exon 19 deletion + EGFR G724S (3)
EGFR exon 19 deletion + NRAS Q61K (3)
EGFR exon 19 deletion + PTEN K237Cfs*17 (3)
EGFR mutation + ANKRD1 overexpression (3)
EGFR mutation + EGFR amplification (3)
EGFR mutation + MET overexpression (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
MET overexpression + EGFR mutation (3)
AXL expression + EGFR mutation (2)
EGFR C797S + EGFR T790M + EGFR exon 19 deletion + TMB-L (2)
EGFR L858R + EGFR exon 19 deletion (2)
EGFR L858R + PD-L1 overexpression (2)
EGFR L858R + VOPP1-EGFR fusion + EGFR T790M (2)
EGFR exon 19 deletion + MET amplification (2)
EGFR exon 19 deletion + EGFR K754E (2)
EGFR exon 19 deletion + EGFR L861Q + EGFR G873E (2)
EGFR exon 19 deletion + KRAS mutation (2)
EGFR exon 19 deletion + PD-L1 expression (2)
EGFR exon 19 deletion + TP53 mutation + RB1 mutation (2)
EGFR exon 20 insertion + EGFR amplification (2)
EGFR mutation + BCL2L11 deletion (2)
EGFR mutation + CDCA3 underexpression (2)
EGFR mutation + PTEN deletion (2)
EGFR mutation + RET fusion (2)
EGFR mutation + YAP1 overexpression (2)
EGFR mutation + YES1 overexpression (2)
EGFR-SEPTIN14 fusion + EGFR amplification (2)
EGFR exon 19 deletion + MET Amplification + MET D1228V (2)
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)
ERBB3 mutation + TMB-H (2)
HER-2 amplification + EGFR-ZNF880 fusion + EGFR E114K (2)
PD-L1 overexpression + EGFR mutation (2)
TMB-H + EGFR exon 19 deletion (2)
TMB-H + EGFR mutation (2)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
APC V2194fs + EGFR amplification + EGFR-SEPTIN14 fusion (1)
APOA1 elevation + EGFR T790M (1)
ARID1A underexpression + EGFR mutation (1)
ATM expression + ATM T2333fs* + EGFR negative (1)
AXL overexpression + EGFR mutation (1)
AXL underexpression + EGFR mutation (1)
BCL2L11 deletion + EGFR T790M (1)
BRAF V600E + EGFR expression (1)
CCDC6-RET fusion + EGFR mutation (1)
CD276 underexpression + EGFR mutation (1)
CD74-NRG1 fusion + EGFR mutation + HER-2 mutation (1)
CRKL overexpression + EGFR mutation (1)
EGFR C797S + KRAS amplification + RB1 deletion (1)
EGFR C797S + MET amplification (1)
EGFR E746_A750del + KRAS amplification (1)
EGFR G719A + EGFR S768I + PD-L1 overexpression (1)
EGFR G719A + PD-L1 overexpression (1)
EGFR G719D + EGFR L861Q + CUX1-MET fusion (1)
EGFR L747P + PD-L1 overexpression (1)
EGFR L747_A750delinsP + MET D1228H + MET D1228N + MET D1228Y + MET Y1230H + MET amplification (1)
EGFR L858R + HER-2 amplification + PIK3CA overexpression (1)
EGFR L858R + KDR overexpression + VEGFC overexpression (1)
EGFR L858R + KRAS amplification + RB1 deletion (1)
EGFR L858R + MET amplification (1)
EGFR L858R + MET overexpression (1)
EGFR L858R + MET positive (1)
EGFR L858R + PD-L1 expression (1)
EGFR L858R + PD-L1 underexpression (1)
EGFR L858R + ROS1 fusion (1)
EGFR L858R + ROS1-ADGRG6 fusion (1)
EGFR L858R + TMB-H (1)
EGFR L858R + VEGFA-L (1)
EGFR P719A + PD-L1 overexpression (1)
EGFR T263P + EGFR L858R + MET amplification (1)
EGFR T790M + HER-2 amplification (1)
EGFR T790M + KRAS amplification + RB1 deletion (1)
EGFR T790M + MET amplification (1)
EGFR T790M + MET positive (1)
EGFR T790M + MYC amplification (1)
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)
EGFR T790M + TMB-H (1)
EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression (1)
EGFR exon 19 deletion + ALK amplification (1)
EGFR exon 19 deletion + BRAF G464A (1)
EGFR exon 19 deletion + CCND1 overexpression (1)
EGFR exon 19 deletion + EGFR L747S (1)
EGFR exon 19 deletion + EGFR S768I (1)
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + HER-2 amplification (1)
EGFR exon 19 deletion + EGFR T790M + PD-L1 expression (1)
EGFR exon 19 deletion + EGFR exon 21 mutation + TP53 mutation (1)
EGFR exon 19 deletion + LMNA-NTRK1 fusion + EGFR T790M (1)
EGFR exon 19 deletion + MET positive (1)
EGFR exon 19 deletion + MET amplification (1)
EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y (1)
EGFR exon 19 deletion + MET amplification + MET D1228H + MET D1228N + MET D1228Y + MET Y1230C (1)
EGFR exon 19 deletion + PD-L1 underexpression (1)
EGFR exon 19 deletion + PTEN deletion + PIK3CA overexpression (1)
EGFR exon 19 deletion + RBM10 S167* (1)
EGFR exon 19 deletion + STRN-ALK fusion (1)
EGFR exon 19 deletion + TP53 mutation + CDK6 amplification + KRAS amplification (1)
EGFR exon 19 deletion + TP53 mutation + MET amplification (1)
EGFR exon 19 deletion + VEGFA-L (1)
EGFR exon 20 insertion + PD-L1 overexpression (1)
EGFR exon 20 insertion + TP53 mutation (1)
EGFR expression + KRAS G12C (1)
EGFR expression + TP53 mutation (1)
EGFR fusion + PD-L1 overexpression (1)
EGFR mutation + ALK negative + TMB-H (1)
EGFR mutation + BCL2L11 overexpression (1)
EGFR mutation + BRCA1 overexpression (1)
EGFR mutation + BRCA1 underexpression (1)
EGFR mutation + CCND1 expression + CDKN2A deletion (1)
EGFR mutation + CD73 overexpression (1)
EGFR mutation + Chr 14q31.1-q31.3 (1)
EGFR mutation + Chr 1p13.3-p13.1 (1)
EGFR mutation + EGFR amplification + MET amplification + MTAP deletion (1)
EGFR mutation + ER positive (1)
EGFR mutation + LANCL2 overexpression (1)
EGFR mutation + LINC00460 overexpression (1)
EGFR mutation + MET amplification + EGFR amplification (1)
EGFR mutation + MET amplification + TP53 mutation (1)
EGFR mutation + MET overexpression + MET amplification (1)
EGFR mutation + MET-CEP7 fusion (1)
EGFR mutation + PD-L1 elevation (1)
EGFR mutation + PD-L1 expression + TP53 mutation (1)
EGFR mutation + PD-L1 negative (1)
EGFR mutation + RBBP8 underexpression (1)
EGFR mutation + ROMO1 overexpression (1)
EGFR mutation + RPS6KB1 amplification (1)
EGFR mutation + S100A9 overexpression (1)
EGFR mutation + SYK overexpression (1)
EGFR mutation + TP53 expression (1)
EGFR mutation + TSLP underexpression (1)
EGFR mutation + TTF1 negative (1)
EGFR mutation + WNT5A expression (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR negative + S100A8 elevation (1)
EGFR negative + S100A9 elevation (1)
EGFR negative + SAA1 elevation (1)
EGFR negative + SAA2 elevation (1)
EGFR overexpression + BRAF V600E (1)
EGFR overexpression + BRAF mutation (1)
EGFR overexpression + KRAS 13D (1)
EGFR overexpression + KRAS mutation (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
EGFR wild-type + Chr 11p11.11-q12.1 (1)
EGFR wild-type + Chr 7q31.1-q31.31 (1)
EGFR wild-type + Chr 9q21.31-q22.2 (1)
EGFR wild-type + MET amplification (1)
EGFR wild-type + MET overexpression (1)
EGFR-SEC61G fusion + EGFR amplification (1)
EGFRvIII mutation + EGFR-SEPTIN14 fusion + EGFR amplification (1)
EPHA2 expression + EGFR mutation (1)
ERCC2 positive + SYP negative + EGFR exon 21 mutation (1)
GPRC6A-RET fusion + EGFR mutation (1)
HER-2 amplification + EGFR mutation (1)
HR negative + EGFR amplification (1)
KIF5B-RET fusion + EGFR exon 19 deletion (1)
KRAS mutation + EGFR amplification (1)
MET exon 14 mutation + EGFR wild-type (1)
MET negative + EGFR mutation (1)
MET overexpression + EGFR wild-type (1)
MET positive + EGFR mutation (1)
NOTCH2-NTRK1 fusion + EGFR L858R (1)
PD-L1 underexpression + EGFR mutation (1)
PTGS2 positive + MET positive + PBK positive + EGFR mutation (1)
RBM10 deletion + EGFR mutation (1)
RBM10 underexpression + EGFR mutation (1)
ROS1 translocation + EGFR wild-type (1)
SHTN1-RET fusion + EGFR mutation (1)
SPECC1-RET fusion + EGFR mutation (1)
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)
TERT mutation + EGFR T790M + EGFR exon 20 insertion (1)
TLN1-RET fusion + EGFR mutation (1)
TRIM24-RET fusion + EGFR mutation (1)
TRIM33-RET fusion + EGFR mutation (1)
CALR elevation + EGFR mutation (0)
HER-2 positive + FGFR1 amplification (0)
PD-L1 underexpression + EGFR wild-type (0)
›
Related tests:
Oncomine™ Dx Target Test (10)
Idylla™ EGFR Mutation Test
Lung Cancer 8-Gene Kit
Oncomine™ Dx Target Test (10)
Idylla™ EGFR Mutation Test
Lung Cancer 8-Gene Kit
Associations
(196)
News
Trials
Search handles
@ADesaiMD
@APassaroMD
@AdnanNagrial
@AnaVManana
@AncelJulienMD
@AndresFCardonaZ
@BenjaminBesseMD
@BiagioMd
@BijoyTelivala
@BoschBarrera
@BrendonStilesMD
@BrunaPellini
@CAudigierValett
@CarlesEscriu
@CharuAggarwalMD
@ChristianRolfo
@ClaudioVladmir
@DevikaDasMD
@DocMCotant
@DoctorJSpicer
@DrBivas
@DrChoueiri
@DrHealeyBird
@DrJNaidoo
@DrMarkAwad
@DrR_DUNNE
@DrSanjayPopat
@DrSteveMartin
@DrVijayPatil11
@DrViteri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@EladSharonMD
@FawziAbuRous
@FordePatrick
@GRecondoMD
@GautschiOliver
@Geeky_Foodie
@GlopesMd
@HHorinouchi
@HenningWillers
@IyengarPuneeth
@JackWestMD
@Jbauml
@JessicaJLinMD
@JordiRemon
@Joshua_Reuss
@JulienMazieres
@Kristel_GT
@Latinamd
@LeXiuning
@LeciaSequist
@LuisERaez1
@LuisLara_M
@LungCancerDr
@MLPOncoData
@MPishvaian
@MarieWislez
@MartinReck2
@Mat_Guc
@NormandBlais
@OncoLucus
@PamelaKunzMD
@PatelOncology
@PatrickCMa1
@RManochakian
@RenoHemonc
@RielyMD
@SKabrajiMD
@SalemGIOncDoc
@SantiCabezas1
@ShaalanBeg
@ShrutiPatelMD
@StephenVLiu
@SuyogCancer
@SyedMAhmedMDPhD
@TiansterZhang
@TommyJohn00
@Tony_Calles
@VamsiVelcheti
@VincentRK
@VivekSubbiah
@YasarHammor
@aakonc
@abraocantoMD
@aftimosp
@antonyruggeri
@bmassutis
@bpiperdi
@bpshah79
@cczielinski
@cdanicas
@christine_lovly
@chulkimMD
@cinthiavgauna
@collin_blakely
@diegoadiazg
@dipeshuprety4
@dplanchard
@dr_yakupergun
@drcbsteer
@drgandara
@drkpavithran
@esinghimd
@g_mountzios
@herbloong
@ipreeshagul
@jonathanloree
@jsoriamd
@lindamahj
@malkadav
@mlazqui
@mtmdphd
@n8pennell
@ns_chd
@oncologician
@pashtoonkasi
@ravikanesvaran
@rdoebele
@rsm2800
@ryangentzler
@saadvikdr
@smitha42
@tehfem
@theabzlab
@trnsltnl
@wangyub
@weldeiry
@weoncologists
@yekeduz_emre
Search handles
@ADesaiMD
@APassaroMD
@AdnanNagrial
@AnaVManana
@AncelJulienMD
@AndresFCardonaZ
@BenjaminBesseMD
@BiagioMd
@BijoyTelivala
@BoschBarrera
@BrendonStilesMD
@BrunaPellini
@CAudigierValett
@CarlesEscriu
@CharuAggarwalMD
@ChristianRolfo
@ClaudioVladmir
@DevikaDasMD
@DocMCotant
@DoctorJSpicer
@DrBivas
@DrChoueiri
@DrHealeyBird
@DrJNaidoo
@DrMarkAwad
@DrR_DUNNE
@DrSanjayPopat
@DrSteveMartin
@DrVijayPatil11
@DrViteri
@Dr_Ivanoncologo
@Dr_R_Kurzrock
@EladSharonMD
@FawziAbuRous
@FordePatrick
@GRecondoMD
@GautschiOliver
@Geeky_Foodie
@GlopesMd
@HHorinouchi
@HenningWillers
@IyengarPuneeth
@JackWestMD
@Jbauml
@JessicaJLinMD
@JordiRemon
@Joshua_Reuss
@JulienMazieres
@Kristel_GT
@Latinamd
@LeXiuning
@LeciaSequist
@LuisERaez1
@LuisLara_M
@LungCancerDr
@MLPOncoData
@MPishvaian
@MarieWislez
@MartinReck2
@Mat_Guc
@NormandBlais
@OncoLucus
@PamelaKunzMD
@PatelOncology
@PatrickCMa1
@RManochakian
@RenoHemonc
@RielyMD
@SKabrajiMD
@SalemGIOncDoc
@SantiCabezas1
@ShaalanBeg
@ShrutiPatelMD
@StephenVLiu
@SuyogCancer
@SyedMAhmedMDPhD
@TiansterZhang
@TommyJohn00
@Tony_Calles
@VamsiVelcheti
@VincentRK
@VivekSubbiah
@YasarHammor
@aakonc
@abraocantoMD
@aftimosp
@antonyruggeri
@bmassutis
@bpiperdi
@bpshah79
@cczielinski
@cdanicas
@christine_lovly
@chulkimMD
@cinthiavgauna
@collin_blakely
@diegoadiazg
@dipeshuprety4
@dplanchard
@dr_yakupergun
@drcbsteer
@drgandara
@drkpavithran
@esinghimd
@g_mountzios
@herbloong
@ipreeshagul
@jonathanloree
@jsoriamd
@lindamahj
@malkadav
@mlazqui
@mtmdphd
@n8pennell
@ns_chd
@oncologician
@pashtoonkasi
@ravikanesvaran
@rdoebele
@rsm2800
@ryangentzler
@saadvikdr
@smitha42
@tehfem
@theabzlab
@trnsltnl
@wangyub
@weldeiry
@weoncologists
@yekeduz_emre
Filter by
Latest
9ms
WATCH: Expert oncologists reflect on the state of molecular testing in NSCLC and how it informs the management of patients with uncommon EGFR mutations. @benlevylungdoc @hopkinskimmel @UMiamiHealth #lungcancer https://t.co/vp5pIxGdHx (@OncLive)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
In #clinicaltrial EA5161, investigators at are testing a new treatment approach for patients with #NSCLC w/ EGFR ex20-ins mutations. For more: https://t.co/pwy12PyvBr cc: @ZPiotrowskaMD, @LeciaSequist (@eaonc)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)
9 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
9ms
Delighted to share our latest paper on the mechanistic modeling of disease progression in EGFR-mutant lung adenocarcinoma: https://t.co/dsB0zfo9rc A special thanks to @MDuruisseaux & to all co-authors from @novadiscovery , @JanssenFRA. (@Claudio_MonT_s)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
Join us for this fun + inspiring “thinktank” to study #EGFR-mutant #lungcancer with a great community! Meet the incredible @jillfeldman4 + @ivybelkins! Link for abstract submission below. Deadline 8/18. #hemeoncfellows @OncoAlert #LCSM @EGFRResisters @EGFRSummit https://t.co/SiobKVyQKA (@christine_lovly)
9 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
9ms
“Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer” presented by Dr Roy S. Herbst and colleagues at the 2023 ASCO Annual Meeting https://t.co/gK0miTQZc6 @DrRoyHerbstYale @ASCO #ASCO23 (@clinadvances)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
9ms
A multiD intervention (radiology, pathology, pharmacy, & oncology) ⬇️⬇️ time to start osimertinib for pts with #EGFR-mutant #NSCLC (5 vs 23 days) by directly analyzing frozen tissue & engaging pharmacy early: https://t.co/FHkNGChqVK #LungCancer #lcsm @IbiayiMD (@JCOOP_ASCO)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
9ms
#Clinicaltrial EA5162, led by @ZPiotrowskaMD and @LeciaSequist of @MGHCancerCenter, will evaluate how well osimertinib works in treating pts w/ advanced #NSCLC w/ EGFR ex20-ins mutations. Learn more here: https://t.co/pwy12PyvBr #lcsm (@eaonc)
9 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
9ms
Honored to write an invited editorial on "Zipalertinib in EGFR Exon 20–Mutant NSCLC" - out now in @JCO_ASCO @ASCO @StephenVLiu - we discuss the role of novel TKIs, and drug development in this rare, but increasingly crowded space! Congrats to the authors on this important… https://t.co/q2gu83PHLN (@CharuAggarwalMD)
9 months ago
EGFR exon 20
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation • EGFR exon 20 insertion • EGFR exon 20 mutation
|
zipalertinib (CLN-081)
9ms
A targeted therapy drug improved survival in pts w/ #lungcancer who have #EGFR mutations. PC3I's @CharuAggarwalMD provided input for @theNCI: “This confirms our practice to test for EGFR mutations and recommend adjuvant targeted therapy with osimertinib” https://t.co/O3AdUxmIdX (@PC3Innovation)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
10ms
Also, I don’t think supportive care docs necessarily know the scope of therapeutic options or outcomes and they are sometimes “brought in” to get pts into hospice. PS3 with stage IV pancreatic cancer is very different than PS3 with untreated EGFR mutant lung cancer. (@Alexmenter)
10 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
Yeah I think oncology gets very nuanced and we don’t expect internists to know this stuff. For example metastatic breast cancer sounds terrible. But with hormonal therapies patients can often live many years with good QOL. Same with EGFR mutated metastatic NSCLC (@INizMD)
10 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
Brilliant overview from biology to trials from @RamalingamMD @WinshipAtEmory on EGFR mutant refractory #lungcancer — great objectives to improve IO therapies for NSCLC in their SPORE program. #Pitt23 @UPMC @UPMCHillmanCC (@TiansterZhang)
10 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
Dr. @ipreeshagul presenting EGFR Mutations in Advanced #NSCLC. #TargetedTherapiesInLungCancer #LungCancer #CancerEducation #cancerGRACE (@cancerGRACE)
10 months ago
Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
Dr. @ipreeshagul is a dynamic ⭐️ speaker - a comprehensive, to-the-point review of current treatment landscape in EGFR-mutated NSCLC including the latest ASCO updates, at Targeted Therapies Forum 2023 @cancergrace (@JessicaJLinMD)
10 months ago
Review
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
@teekayowo gives a poignant introduction and gift for @RamalingamMD @WinshipAtEmory, “who we want to be when we grow up” — giving keynote talk on treatment in refractory EGFR mutant lung cancer #Pitt23 @UPMC @UPMCHillmanCC (@TiansterZhang)
10 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
MET positivity showed predictive value for durable responses with amivantamab plus lazertinib in patients with EGFR-mutated NSCLC whose disease progressed on/after osimertinib and are chemotherapy naïve. @BenjaminBesseMD @GustaveRoussy @ASCO #ASCO23 #lcsm https://t.co/UHG7PDlrer (@OncLive)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib) • Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
10ms
Latest living guideline update on stage IV NSCLC just published. Listen to Dr. @ns_chd share the new updates - including second-line options for patients with EGFR exon 20 insertions or KRAS G12C mutations - & the rationale in our latest podcast episode https://t.co/yIzwf6akKb (@BrittanyEHarvey)
10 months ago
Clinical • EGFR exon 20 • Metastases
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • KRAS G12C • EGFR exon 20 insertion • KRAS G12 • EGFR exon 20 mutation
10ms
Cemiplimab is an immunotherapy drug used to treat advanced non-small cell lung cancer (NSCLC). ROS1 fusion is a genetic variant in NSCLC, while EGFR mutation and ALK fusion are two other common NSCLC genetic variants. (@forista8)
10 months ago
IO biomarker • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
|
EGFR mutation • ALK fusion • ROS1 fusion
|
Libtayo (cemiplimab-rwlc)
10ms
1. First in man study of gleevec in CML. 2. Discovery of EGFR mutations in patients who respond to gefitinib. 3. Whole genome sequencing of the first AML genome. (@rosslevinemd)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
gefitinib • imatinib
10ms
WATCH: Benjamin Besse, MD, PhD, discuss the biomarker analysis of the phase 1/1b CHRYSALIS-2 study of amivantamab & lazertinib in EGFR-mutated #NSCLC. #lcsm | @BenjaminBesseMD @GustaveRoussy https://t.co/HefAm5R0C8 (@TargetedOnc)
10 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
10ms
New in #JIPO "Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries, A Review" by Drs Alali and Saifo https://t.co/DOQ79Op0Bj #lungcancer @MousaMAlali @ANaingMD @weoncologists @OncologyNetwork (@JIPOEditors)
10 months ago
Review • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
Case report of a patient with #EGFR mutant NSCLC who developed an acquired #BRAF V600E mutation on osimertinib as well as leptomeningeal disease and achieved durable control with osimertinib, dabrafenib, and trametinib. #JTOCRR @JTOonline https://t.co/TcycKvLI9x (@StephenVLiu)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • EGFR mutation • BRAF V600
|
Mekinist (trametinib) • Tagrisso (osimertinib) • Tafinlar (dabrafenib)
10ms
Befotertinib another third gneration agent in EGFR mutated NSCLC @Bhosale26Bharat @AshayKarpe59998 @Nandinimenon18 https://t.co/1B3U8IKTTd (@DrVijayPatil11)
10 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Semena (befotertinib)
10ms
First line treatment patterns for patients with EGFR mutant lung cancer in #LATAM #lcsm with @GlopesMd @CPupareli Dr. William William & Jeronimo Rodriguez Cid (@GRecondoMD)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
What is the role of immunotherapy alone or in combination in patients with EGFR mutant lung cancer? Great debate in #LATAMoncologySummit @ClaudioVladmir @GlopesMd @JorgeAlatorreA1 💡 (@GRecondoMD)
10 months ago
Clinical • IO biomarker
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
The "Lazarus Response" in Treatment-Naive, Poor Performance Status Patients With Non-Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Mutation by @coreylangermd #TBT https://t.co/VddAGIsLyd (@ASCOBuzz)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
Benjamin Besse, MD, PhD, discussed phase 1/1b CHRYSALIS-2 data of amivantamab + lazertinib in EGFR-mutated #NSCLC. #lcsm | @BenjaminBesseMD @GustaveRoussy https://t.co/zlllgfab3r (@TargetedOnc)
10 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Rybrevant (amivantamab-vmjw) • Leclaza (lazertinib)
10ms
Lazertinib vs Gefitinib as First-line Treatment in Patients with EGFR-mutated advanced NSCLC: LASER301 Lazertinib vs Gefitinib mPFS➡️20.6 vs 9.7 mo ORR➡️76% vs 76% mDOR➡️19.4 vs 8.3 mo 18-m OS➡️80% vs 72% @JCO_ASCO @OncoAlert https://t.co/62K6Lo7F2q (@dr_yakupergun)
10 months ago
Clinical • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
gefitinib • Leclaza (lazertinib)
10ms
Excited to share our case reports detailing various therapeutic strategies for overcoming EGFR mutations as acquired resistance mechanisms in ALK NSCLC just published in @FrontOncology ⬇️⬇️ #LionelMichaux 👏 @CadranelJ https://t.co/ImlKqSNwm6 (@FalletVincent)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
EGFR mutation
10ms
Are you ready for targeted neoadjuvant therapy for EGFR and KRAS G12C mutant NSCLC? @MNagasaka and @kamarroneMD discuss ongoing trials with these new treatment paradigms. More discussion to come later in the program! #DAVAHawaiiLung https://t.co/CSNPUHba3j (@KE_Gallaway)
10 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
10ms
WATCH: Benjamin Besse, MD, PhD, discusses the main findings of the phase 1/1b CHRYSALIS-2 study in EGFR-mutated #NSCLC. @BenjaminBesseMD @GustaveRoussy https://t.co/g7owFprw5y (@TargetedOnc)
10 months ago
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
#FeatureFriday Today on #FeatureFriday, we are featuring a tweet by Dr. Tejas Patil [@TejasPatilMD] highlighting the importance of comprehensive #NGS and the limitation of PCR assays in the detection of #EGFR mutations in #NSCLC. #MedTwitter (@4baseCare)
10 months ago
Next-generation sequencing
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
10ms
#ILCC23 what to do at the time of PD from acquired resistance in oncogene-driven NSCLC? Empiric or biomarker-related decision making? Is paradigm different for EGFR-mutated vs ALK vs METex14 vs KRAS G12C? Come listen to our panel discussion @HwakeleeMD @DrRoyHerbstYale @gotoPER (@drgandara)
10 months ago
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
|
KRAS mutation • EGFR mutation • KRAS G12C • KRAS G12
11ms
New in #JIPO "Optimizing the Treatment for Advanced Non–Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries, A Review" by Drs Alali and Saifo https://t.co/DOQ79Op0Bj #lungcancer @MousaMAlali @ANaingMD @weoncologists @OncologyNetwork (@JIPOEditors)
11 months ago
Review • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
11ms
At #ASCO23, @DrRoyHerbstYale presented overall survival data for adjuvant osimertinib in resected, EGFR-mutated NSCLC. Read a recap in #ILCN: https://t.co/b40STpBg2f #LCSM (@IASLC)
11 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • TPBG (Trophoblast Glycoprotein)
|
EGFR mutation
|
Tagrisso (osimertinib)
11ms
@jillfeldman4 & I just finished taping: “EGFR mutations are not all the same: the importance of biomarker testing in non-small cell lung cancer (NSCLC)—a podcast discussion between patients and oncologists” w/Drs. Sarah Goldberg and @StephenVLiu. Stay tuned @EGFRResisters! #lcsm (@ivybelkins)
11 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
11ms
My answer would be no. I dont think we have enough data but retrospective evidence suggests patients EGFR-mutated NSCLC do not benefit with consolidation durvalumab and experienced a high frequency of irAEs. https://t.co/Pa5skwPQe8 (@TkarawadiaMD)
11 months ago
Retrospective data
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Imfinzi (durvalumab)
11ms
What value does ctDNA have for monitoring pts with resected #EGFR NSCLC? Report @JTOonline of 278 pts with resected stage I-IIIA EGFR mutant NSCLC (2015-2017) who had longitudinal ddPCR: 24% positive pre-op (42% of IIIA): 76% of those clear after surgery. https://t.co/mrTUvA0Ar6 (@StephenVLiu)
11 months ago
Clinical • Surgery • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
11ms
Abstract LBA9000: Pemetrexed and platinum +/- pembrolizumab for TKI-resistant, EGFR-mutant, metastatic nonsquamous NSCLC (KEYNOTE-789) by James CH Yang. Well-powered but "MARGINALLY" negative like CheckMate 722. No durable response even in ICI responders. #ASCO23 #LCSM (@HHorinouchi)
11 months ago
Late-breaking abstract • Metastases
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Keytruda (pembrolizumab) • pemetrexed
11ms
Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR‑mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC) [2023] @DrRoyHerbstYale et al. #ASCO23 LBA3 https://t.co/XvquwuG39L #lcsm #PrecisionMedicine (@mtmdphd)
11 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
11ms
From #ASCO23, Thomas John discusses the results from the ADAURA study of adjuvant osimertinib in patients with resected EGFR mutated stage IB–IIIA non-small cell lung cancer. https://t.co/hXAY1yGMnj @TommyJohn00 #NSCLC #EGFRm #LCSM (@myESMO)
11 months ago
Clinical
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
Tagrisso (osimertinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login